What is Staar Surgical's market cap?

Staar Surgical (STAA) has a market capitalization of $1.4B and trades on NASDAQ.

What is Staar Surgical's revenue and profitability?

Staar Surgical generated $290.4M in trailing twelve-month revenue with a net loss of $21.0M, representing a net margin of -7.2%. Gross margin stands at 76.9%, with free cash flow of -$56.8M. These figures are based on the Q2 2026 filing.

Who are Staar Surgical's competitors?

Staar Surgical's key competitors include Alcon, Johnson & Johnson, Bausch Health Companies, and others. These companies compete in similar markets and product categories.

Who does Staar Surgical partner with?

Staar Surgical's notable partners include Broadwood Partners, L.P..

What subsidiaries does Staar Surgical have?

Staar Surgical's subsidiaries include STAAR Surgical AG, STAAR Japan Inc..

Where is Staar Surgical headquartered?

Staar Surgical is headquartered in United States of America and employs approximately 1,115 people. It has been publicly traded since 1983.

Staar Surgical

STAA

STAAR Surgical Company is a leading medical device manufacturer dedicated to ophthalmic surgery, specializing in the design and production of implantable lenses for the eye.

Market cap

$1.39B+57.9%

Revenue$290.4M+4.0%

Net income-$21.0M+70.4%

Free cash flow-$56.8M-81.1%

EPS (diluted)-$0.42+70.8%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2027 report

May 13, 2026

Revenue$93.5MBeat by $14.8M EPS$0.38Beat by $0.33

Read the full report

Next report

Aug 12, 2026 (in a month)

Revenue estimate$90.2M

EPS estimate$0.21

Financials

Q1 2026

Income statement

See full

Revenue$93.5M+120%

Gross profit$68.9M+146%

Operating income$8.0M+114%

Net income$5.2M+110%

EPS (diluted)$0.10+109%

Balance sheet

See full

Cash & equivalents$131.9M-23.8%

Total debt$37.3M+1.7%

Total equity$352.4M+0.7%

Total assets$451.1M-1.4%

Cash flow

See full

Operating cash flow-$21.7M-278%

CapEx$443.0K-69.8%

Free cash flow-$22.1M-207%

Valuation & ratios

Valuation

See full

Market cap$1.39B+57.9%

Enterprise value$1.3B+89.2%

P/S4.8×+1.9×

Profitability

See full

Gross margin76.9%+2.9pp

Operating margin-9.1%-3.5pp

Net margin-7.2%-3.0pp

FCF margin-19.6%+55.9pp

Returns & leverage

See full

Return on equity-6%-2.4pp

Debt / equity0.1×0.0×

Current ratio5.1×+0.3×

Segments

By geography

See full

Other Countries$19.2M+0.4%

Competitors

By market cap

Johnson & Johnson$623.71B+66.9%

Alcon$32.7B-23.7%

Glaukos$9.1B+57.1%

Bausch Health Companies$1.8B-28.5%

IAR

Integra LifeSciences$1.4B+44.4%

Staar Surgical$1.4B+69.3%

Schering-Plough$671.0M—

LENSAR, Inc.$72.8M-52.4%

By revenue growth

Glaukos+36.3%

Bausch Health Companies+8.2%

Johnson & Johnson+7.9%

Staar Surgical+4.0%

IAR

Integra LifeSciences+1.2%

LENSAR, Inc.+1.1%

By net margin

LENSAR, Inc.50.94%+150pp

Johnson & Johnson21.83%-2.6pp

Bausch Health Companies-1.88%-9.1pp

Staar Surgical-7.24%+18.2pp

IAR

Integra LifeSciences-30.15%-27.0pp

Glaukos-34.34%-3.8pp

Profile

STAAR Surgical Company is a leading medical device manufacturer dedicated to ophthalmic surgery, specializing in the design and production of implantable lenses for the eye. The company's core value proposition centers on its proprietary Collamer material, a biocompatible collagen copolymer used to create the EVO family of Implantable Collamer Lenses (ICLs). These lenses provide a premium, reversible alternative to laser-based refractive surgeries for patients seeking visual freedom from eyeglasses or contact lenses.

Competitive position

STAAR is the leading manufacturer of phakic implantable lenses worldwide and holds a unique position as the provider of the only FDA-approved posterior chamber phakic IOL in the United States.

GeographiesUnited States, China, Japan, Switzerland, Germany, Spain, Singapore, Canada, United Kingdom, South Korea, India, France

Customer segmentsHealthcare Providers, Specialized Clinics, Distributors

Business modelManufacturing, Direct Sales, Distributor-led Sales

SuppliersBiological collagen sources, Synthetic monomer suppliers, Single-source raw material vendors, Medical-grade component manufacturers

CustomersOphthalmologists, Refractive surgery clinics, Medical device distributors, Public and private hospitals

CountryUnited States of America

Listed1983

Employees1.1K

CEOWarren Foust

SectorHealthcare

IndustryMedical - Instruments & Supplies

Websitestaar.com

FilingsSEC EDGAR

Ask your AI about Staar Surgical.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Staar Surgical's market cap?: Staar Surgical (STAA) has a market capitalization of $1.4B and trades on NASDAQ.
What is Staar Surgical's revenue and profitability?: Staar Surgical generated $290.4M in trailing twelve-month revenue with a net loss of $21.0M, representing a net margin of -7.2%. Gross margin stands at 76.9%, with free cash flow of -$56.8M. These figures are based on the Q2 2026 filing.
Who are Staar Surgical's competitors?: Staar Surgical's key competitors include Alcon, Johnson & Johnson, Bausch Health Companies, and others. These companies compete in similar markets and product categories.
Who does Staar Surgical partner with?: Staar Surgical's notable partners include Broadwood Partners, L.P..
What subsidiaries does Staar Surgical have?: Staar Surgical's subsidiaries include STAAR Surgical AG, STAAR Japan Inc..
Where is Staar Surgical headquartered?: Staar Surgical is headquartered in United States of America and employs approximately 1,115 people. It has been publicly traded since 1983.